Compare TPC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPC | LQDA |
|---|---|---|
| Founded | 1894 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.0B |
| IPO Year | 2003 | 2020 |
| Metric | TPC | LQDA |
|---|---|---|
| Price | $98.95 | $57.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $118.00 | $63.88 |
| AVG Volume (30 Days) | 575.1K | ★ 3.1M |
| Earning Date | 11-04-2026 | 11-10-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | ★ 148.24 | 51.81 |
| EPS | ★ 2.09 | N/A |
| Revenue | ★ $5,543,039,000.00 | $158,320,000.00 |
| Revenue This Year | $16.91 | $379.72 |
| Revenue Next Year | $14.12 | $17.90 |
| P/E Ratio | $47.82 | ★ N/A |
| Revenue Growth | 28.11 | ★ 1031.18 |
| 52 Week Low | $57.90 | $22.31 |
| 52 Week High | $102.30 | $93.61 |
| Indicator | TPC | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 70.22 | 67.76 |
| Support Level | $76.48 | $53.06 |
| Resistance Level | $101.15 | $63.46 |
| Average True Range (ATR) | 4.19 | 3.42 |
| MACD | 2.33 | 2.35 |
| Stochastic Oscillator | 85.91 | 91.35 |
Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically it derives key revenue from the United States.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.